Journal
PHARMACOGENOMICS
Volume 21, Issue 10, Pages 705-720Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2020-0021
Keywords
-
Categories
Funding
- Centre National de la Recherche Scientifique [UMR 7369]
- INSERM [UMR-S1250]
- University of Reims Champagne-Ardenne
Ask authors/readers for more resources
Immunotherapies are now considered as a pillar of non-small-cell lung cancer treatment. The main targets of immune-checkpoint inhibitors (ICI) are programmed cell death 1/programmed cell death ligand 1 and cytotoxic T-lymphocyte antigen 4, aiming at restoring antitumor immunity. Despite durable responses observed in some patients, all patients do not benefit from the treatment and almost all responders ultimately relapse after some time. In this review, we discuss the biomarkers that could be used to predict response to ICI, the current indications of ICI in non-small-cell lung cancer, the mechanisms inducing tumor-cell intrinsic or extrinsic resistance to ICI and finally, the potential treatment response monitoring.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available